mTOR

LGB321 is a selective mTOR-C1 inhibitor that effectively disrupts PIM2-dependent signaling pathways in multiple myeloma cell lines. This compound inhibits cell proliferation and modulates key cellular processes, including the phosphorylation of BAD. LGB321 is valuable for research focused on understanding the mechanisms of multiple myeloma and the mTOR signaling pathway.

PI3K/mTOR-IN-18 is a highly selective dual inhibitor targeting PI3Kα and mTOR, with binding affinities of Ki=0.130 nM and Ki=0.111 nM, respectively. This compound effectively blocks the PI3K/AKT/mTOR signaling pathway, resulting in significant inhibition of tumor cell proliferation (IC50=144 nM). PI3K/mTOR-IN-18 is suitable for research involving various solid tumors, including breast cancer and non-small cell lung cancer (NSCLC).

PI3K/mTOR Inhibitor-14 is a dual inhibitor targeting phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), exhibiting IC50 values of 171.4 nM and 10.1 nM, respectively. This compound demonstrates significant antitumor activity, making it a valuable tool for cancer research. Its inhibition of the PI3K/mTOR signaling pathway can be critical for studies focused on cell proliferation and survival in various cancer models.

PI3K/mTOR Inhibitor-7 (Compound 19i) is a potent dual inhibitor targeting the PI3K and mTOR pathways. It demonstrates a 4.7-fold increased potency compared to the positive control gedatolisib, with an IC50 of 0.3 μM. At a concentration of 10 μM, PI3K/mTOR Inhibitor-7 effectively suppresses the PI3K/Akt/mTOR signaling pathway. This compound is valuable for research applications focused on cancer biology and related therapeutic development.

mTOR inhibitor-18 is a selective inhibitor of the mechanistic target of rapamycin (mTOR). It exhibits significant activity in modulating intracellular signaling pathways associated with cell growth, proliferation, and survival. This compound is particularly useful in researching various conditions, including cancer, immune disorders, cardiovascular diseases, viral infections, inflammation, and metabolic or endocrine function disorders. Its role in neurological research further highlights its versatility as a critical tool in understanding mTOR-related biological processes.

PI3K/mTOR Inhibitor-6 is a potent dual inhibitor targeting the phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) pathways. This compound demonstrates enhanced stability in artificial gastric fluids compared to other PI3K/mTOR inhibitors. At a concentration of 10 μM, PI3K/mTOR Inhibitor-6 effectively suppresses the PI3K/Akt/mTOR signaling pathway, highlighting its potential for cancer research applications.

P-2281 is an mTOR inhibitor that exhibits significant anticancer and anti-inflammatory properties. It effectively inhibits mTOR activity in colon cancer cells and suppresses Dextran sulfate sodium salt (DSS)-induced colitis by modulating T cell function. P-2281 has demonstrated efficacy in murine models of human colitis, making it a valuable tool for research into cancer therapies and inflammatory bowel diseases.

CC-M-1 is a potent and selective inhibitor of the PI3K/mTOR signaling pathway, targeting PI3Kα/β/γ/δ and mTOR with IC50 values of 0.68, 1.02, 1.03, 8.03, and 15 nM, respectively. This compound demonstrates significant inhibition of proliferation in colorectal cancer cell lines, including HCT-116 (IC50 = 0.38 μM) and HT-29 (IC50 = 1.70 μM). CC-M-1 serves as a valuable tool for researchers investigating colorectal cancer (CRC) therapeutic strategies and the underlying mechanisms of tumorigenesis.

PI3K/mTOR Inhibitor-13 is a potent, orally active dual inhibitor targeting phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR). This compound demonstrates significant biological activity against various pathologies, including solid tumors, sexual diseases, and idiopathic pulmonary fibrosis (IPF). It serves as a valuable tool for cancer research and therapeutic development related to these conditions.

mTOR inhibitor-13 is a selective inhibitor of mammalian target of rapamycin (mTOR) with an IC50 value of 0.29 nM, demonstrating potent inhibition. Additionally, this compound exhibits activity against PI3K-α with an IC50 of 119 nM. It is primarily utilized in research applications related to cancer, metabolic disorders, and cellular growth regulation, making it a valuable tool for investigating mTOR-mediated pathways.

mTOR inhibitor-17 is a selective inhibitor of the mechanistic target of rapamycin (mTOR), exhibiting an IC50 of 0.68 nM. This compound effectively inhibits cell proliferation in LNCaP prostate cancer cells with an IC50 of 40 nM. It is utilized in research to investigate the role of mTOR signaling in cancer metabolism and therapy.

mTORC1-IN-2 is an inhibitor of the mechanistic target of rapamycin complex 1 (mTORC1). This compound functions by upregulating the expression of TSC2-P while concurrently inhibiting mTORC1 signaling. It exhibits vasodilatory effects and offers protection against myocardial hypoxic injury, making it a valuable tool for research in cardiovascular and metabolic disorders. Its impact on mTORC1 signaling pathways underscores its potential in studies related to cellular growth, proliferation, and survival.

mTOR inhibitor-24 (compound 9d) is a potent mTOR inhibitor, exhibiting an IC50 of 0.34 nM against mTOR and 324 nM against PI3K-α. This compound effectively inhibits the proliferation of LNCaP cells with an IC50 of 180 nM. It serves as a valuable tool for research in cancer biology and therapeutic exploration targeting the mTOR signaling pathway.

PF-06465603 is a potent and selective ATP-competitive inhibitor targeting the mTOR pathway. This compound serves as a valuable research tool for studying the regulation of cell growth, proliferation, and survival through mTOR signaling. As a metabolite of PF-04691502, PF-06465603 features a terminal carboxylic acid structure, further facilitating investigations into its biological activity and therapeutic potential in various diseases, including cancer and metabolic disorders.

mTOR inhibitor-16 (Compound 9f) is a selective inhibitor of the mechanistic target of rapamycin (mTOR). It demonstrates potent inhibitory activity against mTOR and PI3K-α, with IC50 values of 1.25 nM and 82 nM, respectively. This compound effectively inhibits the proliferation of LNCaP prostate cancer cells, with an IC50 of 140 nM, making it a valuable tool for cancer research and studies involving the mTOR signaling pathway.

NSC126405 is an mTOR-DEPTOR inhibitor that disrupts the interaction between mTOR and DEPTOR, leading to enhanced cytotoxicity in multiple myeloma cells. This compound serves as a valuable tool in cancer research, allowing for the exploration of mTOR signaling pathways and potential therapeutic strategies in hematological malignancies.

WJD008 is a potent dual inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), specifically targeting PI3K α and mTOR kinase activities. It exhibits significant antiproliferative and anticlonogenic effects in tumor cells, particularly those with PIK3CA mutations. By disrupting the insulin-like growth factor-I-activated PI3K-Akt-mTOR signaling pathway, WJD008 holds promise for advancing cancer research and therapeutic strategies.

mTOR inhibitor-10 (Compound 9c) is a selective inhibitor targeting the mechanistic target of rapamycin (mTOR). This compound effectively inhibits both mTOR and PI3K-α, demonstrating IC50 values of 0.7 nM and 825 nM, respectively. mTOR inhibitor-10 exhibits significant anti-proliferative activity against LNCaP cancer cells, with an IC50 value of 87 nM, making it a valuable tool for research in cancer biology and therapeutic applications.

NVP-BBD130 is a potent dual inhibitor of PI3K and mTOR, functioning through ATP-competitive mechanisms. This compound demonstrates significant stability and provides effective oral bioavailability. Additionally, NVP-BBD130 serves as a click chemistry reagent due to its alkyne group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules. Its versatility makes it suitable for various research applications in cancer therapy and biochemical signaling pathways.